Page last updated: 2024-09-04

docetaxel anhydrous and tasquinimod

docetaxel anhydrous has been researched along with tasquinimod in 2 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (tasquinimod)	Trials (tasquinimod)	Recent Studies (post-2010) (tasquinimod)
12,110	3,216	6,920	49	9	42

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Becker, RE; Dalrymple, SL; Isaacs, JT	1
Baton, F; Bellmunt, J; Chowdhury, S; Climent, MA; Daugaard, G; Dumez, H; Fizazi, K; Flechon, A; Germann, N; Guida, A; Ladoire, S; Liutkauskiene, S; Matouskova, M; Moe, M; Penel, N; Sengeløv, L; Stachurski, L; Sternberg, CN; Thiery-Vuillemin, A; Ulys, A	1

Trials

1 trial(s) available for docetaxel anhydrous and tasquinimod

Article	Year
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; International Agencies; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quinolones; Survival Rate; Taxoids; Treatment Outcome	2017

Article

Year

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:11

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; International Agencies; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quinolones; Survival Rate; Taxoids; Treatment Outcome

2017

Other Studies

1 other study(ies) available for docetaxel anhydrous and tasquinimod

Article	Year
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. The Prostate, 2007, May-15, Volume: 67, Issue:7 Topics: Androgens; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Quinolines; Quinolones; Survival Analysis; Taxoids; Xenograft Model Antitumor Assays	2007

Article

Year

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.

The Prostate, 2007, May-15, Volume: 67, Issue:7

Topics: Androgens; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Quinolines; Quinolones; Survival Analysis; Taxoids; Xenograft Model Antitumor Assays

2007